REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.
Back to Research Library
liraglutidesemaglutidetirzepatide

Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.

May 16, 2026
Share

Source Paper

Medications for Obesity: A Review.

Gudzune Kimberly A et al.JAMA2024
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Modern Anti-Obesity Drugs: A Game-Changer in Weight Management

Published: May 16, 2026 | Source: JAMA (2024) | Category: liraglutide, semaglutide, tirzepatide

Overview

A recent review published in JAMA highlights the significant weight loss benefits of modern anti-obesity medications like liraglutide, semaglutide, and tirzepatide when used alongside lifestyle changes. This research underscores a promising new era for peptide therapy in combating obesity-related health risks.

Study Background

Obesity is a global epidemic affecting nearly 19% of women and 14% of men worldwide, contributing to increased morbidity from conditions such as type 2 diabetes, hypertension, and dyslipidemia. Prior research has shown that anti-obesity medications (AOMs) can modify biological processes related to appetite, but their efficacy and safety profiles have been inconsistent. This review aimed to synthesize data from multiple clinical trials to provide a clearer understanding of the benefits and risks associated with these drugs.

What the Research Found

The meta-analysis revealed substantial weight loss benefits for liraglutide (4.7% greater than placebo), semaglutide (11.4%), and tirzepatide (12.4%) when used in conjunction with lifestyle interventions. These medications mimic enteropancreatic hormones that regulate appetite, leading to significant improvements not only in weight but also in cardiometabolic health markers such as blood pressure, cholesterol levels, and glucose control.

Specifically:

  • Liraglutide: 6321 participants across 18 randomized clinical trials showed a 4.7% greater weight loss compared to placebo.
  • Semaglutide: 4421 participants across 5 RCTs demonstrated an 11.4% greater weight loss than placebo.
  • Tirzepatide (15 mg): 1972 participants in 6 RCTs experienced a 12.4% greater weight loss compared to placebo.

These drugs also exhibited fewer gastrointestinal adverse effects compared to orlistat, with common side effects including nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%).

What This Means for Peptide Users

For individuals managing obesity through peptide therapy, this research suggests that incorporating liraglutide, semaglutide, or tirzepatide into their regimen could yield significant weight loss benefits. These medications offer a more targeted approach to appetite regulation and metabolic health improvement compared to traditional anti-obesity drugs.

Limitations and Caveats

While the findings are promising, several limitations must be acknowledged:

  • Methodological Variability: The study relies on data from multiple clinical trials with varying methodologies and patient populations, which may affect generalizability.
  • Long-Term Safety: Long-term safety profiles of these medications remain less understood compared to their short-term efficacy.
  • Patient Adherence: Compliance with lifestyle interventions alongside medication use can be challenging for some patients.

How This Compares to Previous Research

Previous studies have shown mixed results regarding the effectiveness and side effect profiles of anti-obesity drugs. However, this review consolidates evidence from numerous clinical trials, providing a more robust assessment of modern medications like liraglutide, semaglutide, and tirzepatide.

Our Analysis

PeptideVault's analysis indicates that while these findings are encouraging for patients seeking effective weight management solutions, caution is warranted due to the limitations noted. The data suggests a significant potential benefit from using these peptide-based medications in conjunction with lifestyle changes, but further research is needed to fully understand long-term outcomes and safety.

Key Takeaways

  • Efficacy: Modern anti-obesity drugs like liraglutide, semaglutide, and tirzepatide offer substantial weight loss benefits when used alongside lifestyle interventions.
  • Safety Profile: These medications have fewer gastrointestinal side effects compared to older drugs but may cause nausea, diarrhea, and constipation in some patients.
  • Further Research Needed: Long-term safety studies are essential for a comprehensive understanding of these treatments.

Original Source

Citation: Gudzune Kimberly A, Kushner Robert F (2024). Medications for Obesity: A Review.. JAMA. DOI: 10.1001/jama.2024.10816

Access: https://pubmed.ncbi.nlm.nih.gov/39037780/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

semaglutideGLP-1 receptor agonist

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimetics

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.